AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02133027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rouviere's sulcus
Description: Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
Study NCT02133027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical instruments
Description: surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
Study NCT02133027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: surgical instruments
Description: surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
Study NCT00227903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT
Description: Motivationally-enhanced cognitive behavioral skills counseling
Study NCT00227903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Advice and education
Study NCT01533233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic lobectomy and mediastinal lymph node dissection
Study NCT01533233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic lobectomy and mediastinal lymph node dissection
Study NCT01541969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR Neuromodulation
Description: Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour.
Study NCT01541969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tinnitus masking
Description: The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
Study NCT00604331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvate
Description: sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
Study NCT04750720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling by venipuncture (and eventually by nasopharyngeal swab)
Description: Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells
Study NCT04743427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot pack and exercises
Description: 20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
Study NCT04743427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body blade(BB)
Description: The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
Study NCT00849381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299, GSK Biological's HPV vaccine
Description: All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
Study NCT04599920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partial replacement of red meat with legume-based foods
Description: 560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
Study NCT04599920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partial replacement of red meat with legume-based foods
Description: 560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
Study NCT04237090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Drug identification number : 02369567
Study NCT04237090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Drug identification number : 02231603
Study NCT04237090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactose pill
Description: Natural product number : 00501190
Study NCT04237090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9%
Description: Drug identification number : 00037796
Study NCT02947529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous dose
Study NCT02562937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text messages related to sedentary behaviour
Description: texts sent twice daily encouraging reduced sedentary behaviour
Study NCT04987528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aminoterminal type III peptide of procollagen
Description: Serial Measurement of PIIINP in serum and/or BAL
Study NCT04987528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung computed tomography
Description: Screening for the presence of reticulation or bronchiectasia within lung parenchyma
Study NCT02423005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurotech Vital Compact
Description: Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
Study NCT02423005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: itouch Sure Pelvic Floor Exerciser
Description: Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
Study NCT04707820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPOT
Description: The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein.
Study NCT03287232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Insert
Description: Daily administration of a placebo vaginal insert.
Study NCT03287232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone 6.5 mg (0.50%) Vaginal Insert
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Study NCT03251456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tertiary care
Description: 1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary.
Study NCT03251456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary.
Study NCT01262456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Study NCT01262456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desmopressin
Study NCT02822378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: All participants will consume vitamin D supplements for the duration of baseline and intervention.
Study NCT01262456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02130336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Study NCT02130336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity exercise
Study NCT03209076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: Robotic low anterior resection
Study NCT03209076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic
Description: Laparoscopic low anterior resection
Study NCT03659149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation I
Description: 1 tablet administered before the breakfast(single-dose)
Study NCT02947529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous dose
Study NCT02765126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Intramuscular standard seasonal influenza vaccine
Study NCT02765126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular DTaP vaccine
Study NCT03673605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Description: Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
Study NCT03673605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study NCT03659149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)
Study NCT03659149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)
Study NCT02186054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI examinations
Description: Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
Study NCT02614807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
Study NCT01833260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Study NCT01007123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study
Study NCT01007123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study
Study NCT00076336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600mg/day oral tablet for 104 weeks
Study NCT00076336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100mg/day oral tablet for 104 weeks
Study NCT00076336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.
Study NCT00076336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.
Study NCT01206283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Lund concept
Description: After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg.
Study NCT01206283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral perfusion pressure-targeted therapy
Description: * ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);
Study NCT00524589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: IV
Study NCT00524589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control
Study NCT03929198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: 6 week Diet, Exercise training, Behavioral modification
Study NCT04085952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dermal graft (ARCUS repliform) for anterior colporrhaphy
Description: At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
Study NCT04085952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture based anterior colporrhaphy
Description: At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
Study NCT04027452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traumatic memory reactivation
Description: 125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.
Study NCT04027452 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral memory reactivation
Description: 125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.
Study NCT03719352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Deep dry needling
Description: Deep dry needling until achieving twitch response of the muscle
Study NCT03719352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Superficial dry needling
Description: Superficial dry needling to achieve sensitive pain with needle rotation
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain apple compote control
Study NCT03356795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervical cancer-specific CAR-T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study NCT04096469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
Study NCT04096469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
Study NCT01676649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg
Study NCT01676649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 6
Study NCT01676649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2
Study NCT00524589 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative Study
Study NCT00524589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study NCT02060994 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00881764 — intervention group
Intervention type: PROCEDURE
Intervention: Inguinal hernia surgery
Description: Non-experimental procedure
Study NCT00881764 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Non-experimental procedure/treatment
Study NCT04101162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: shear waves elastography; liver biopsy
Description: Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
Study NCT04214470 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT00887094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Description: Aerobic exercise (on a cycle ergometer, for 50 min)
Study NCT00887094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute aerobic-resistance exercise
Description: Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)